Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you consider a PARP inhibitor in a patient who harbors a germline BRCA mutation who has metastatic HER2 negative gastric cancer?
Related Questions
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
In a patient with a mid-esophageal squamous cell carcinoma with tracheal invasion confirmed on bronchoscopy, would you treat with definitive chemo-radiation with curative intent?
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?
How would you manage a middle thoracic esophageal squamous cell carcinoma (tumor is 25-30 cm from carina) with a positive supra-clavicular lymph node?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?
Is there a standard of care for management of localized DNA mismatch repair deficient esophagus cancer?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
Would you offer zolbetuximab in a non-Asian population?
How was treatment response assessed on the PROSPECT trial?
